We examined the relation between
adalimumab and
infliximab plasma trough levels, anti-
adalimumab and anti-
infliximab antibody formation. We analyzed plasma from 32
adalimumab-treated and 20
infliximab-treated
psoriasis patients for evaluating trough levels of each
drug. The presence of anti-
adalimumab and anti-
infliximab antibodies was analyzed and the severity of
psoriasis was evaluated. At week 28, 25 out of 32 and at week 48, 21 out of 30
adalimumab-treated patients maintained as more than PASI 75. At week 28, 12 out of 20 and at week 48, nine out of 18
infliximab-treated patients were evaluated as more than PASI 75. In patients treated with 40 mg
adalimumab every other week, the mean trough level was 7.62 μg/mL (range, 0.05-10.6) at week 48. In patients treated with 80 mg
adalimumab every other week, the mean trough level was 8.61 μg/mL (range, 0.08-13.5) at week 48. Mean trough level of
infliximab-treated cases (4.1-5.2 mg/kg; mean, 4.6) was 4.64 μg/mL (range, 0.03-16.9) at week 48. Anti-
adalimumab antibody was detected in five out of 32 cases and anti-
infliximab antibody was detected in six out of 20 cases, respectively, at weeks 24 and 48. The optimal cut-off values of
adalimumab and
infliximab concentration for more than PASI 75 were more than 7.84 μg/mL and more than 0.92 μg/mL, respectively. The trough levels of
adalimumab and
infliximab in
psoriasis patients were positively associated with clinical response and were significantly lower in cases having anti-
adalimumab or anti-
infliximab antibodies.